Neurocognitive profile in HIV subjects on INSTI-regimen- one year follow up: Is there room for optimism?

ABSTRACT: The introduction of antiretroviral therapy (ART) has successfully changed the clinical course of people with HIV, leading to a significant decline in the incidence of HIV-related neurocognitive disorders. Integrase strand transferase inhibitors (INSTI) are recommended and preferred first-line ART for the treatment of HIV-1 infection in ART-naïve subjects. This type of therapy regimen is expected to have higher CNS penetration, which may bring more cognitive stability or even make significant cognitive improvement in people with HIV. The study aimed to follow up on neurocognitive performance in HIV subjects on two types of INSTI therapy regimens at two-time points, one year apart. The study sample consisted of 61 ART naïve male participants, of which 32 were prescribed raltegravir (RAL) and

SUBMITTER: Brkic-Jovanovic N 

PROVIDER: S-EPMC11207154 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature